

**CHARITABLE PRESCRIPTION DRUG RECYCLING  
PROGRAM**

2016 GENERAL SESSION

STATE OF UTAH

**Chief Sponsor: Gage Froerer**

Senate Sponsor: \_\_\_\_\_

---

---

**LONG TITLE**

**General Description:**

This bill creates a program that allows certain pharmacies to accept and dispense donated unused prescription medications to certain individuals.

**Highlighted Provisions:**

This bill:

- ▶ amends the Pharmacy Practice Act;
- ▶ defines terms;
- ▶ directs the Division of Occupational and Professional Licensing (DOPL) to make rules, in consultation with the Utah State Board of Pharmacy, to create a charitable prescription drug recycling program;
- ▶ establishes criteria for prescription drugs eligible for the program;
- ▶ establishes requirements for donors and pharmacies;
- ▶ limits the liability of program participants;
- ▶ directs DOPL to make rules establishing certain requirements, standards, procedures, and processes; and
- ▶ makes technical changes.

**Money Appropriated in this Bill:**

None

**Other Special Clauses:**



28 None

29 **Utah Code Sections Affected:**

30 AMENDS:

31 **58-17b-502**, as last amended by Laws of Utah 2015, Chapter 336

32 **58-17b-503**, as last amended by Laws of Utah 2011, Chapter 366

33 ENACTS:

34 **58-17b-901**, Utah Code Annotated 1953

35 **58-17b-902**, Utah Code Annotated 1953

36 **58-17b-903**, Utah Code Annotated 1953

37 **58-17b-904**, Utah Code Annotated 1953

38 **58-17b-905**, Utah Code Annotated 1953

39 **58-17b-906**, Utah Code Annotated 1953

40 **58-17b-907**, Utah Code Annotated 1953



42 *Be it enacted by the Legislature of the state of Utah:*

43 Section 1. Section **58-17b-502** is amended to read:

44 **58-17b-502. Unprofessional conduct.**

45 "Unprofessional conduct" includes:

46 (1) willfully deceiving or attempting to deceive the division, the board, or their agents  
47 as to any relevant matter regarding compliance under this chapter;

48 (2) (a) except as provided in Subsection (2)(b):

49 (i) paying or offering rebates to practitioners or any other health care providers, or  
50 receiving or soliciting rebates from practitioners or any other health care provider; or

51 (ii) paying, offering, receiving, or soliciting compensation in the form of a commission,  
52 bonus, rebate, kickback, or split fee arrangement with practitioners or any other health care  
53 provider, for the purpose of obtaining referrals.

54 (b) Subsection (2)(a) does not apply to:

55 (i) giving or receiving price discounts based on purchase volume;

56 (ii) passing along pharmaceutical manufacturer's rebates; or

57 (iii) providing compensation for services to a veterinarian.

58 (3) misbranding or adulteration of any drug or device or the sale, distribution, or

- 59 dispensing of any outdated, misbranded, or adulterated drug or device;
- 60 (4) engaging in the sale or purchase of drugs or devices that are samples or packages  
61 bearing the inscription "sample" or "not for resale" or similar words or phrases;
- 62 (5) except as provided in Section [58-17b-503](#) or [Part 9, Charitable Prescription Drug](#)  
63 [Recycling Act](#), accepting back and redistributing [of] any unused drug, or a part of it, after it  
64 has left the premises of any pharmacy, unless the drug is in a unit pack, as defined in Section  
65 [58-17b-503](#), or the manufacturer's sealed container, as defined in rule;
- 66 (6) an act in violation of this chapter committed by a person for any form of  
67 compensation if the act is incidental to the person's professional activities, including the  
68 activities of a pharmacist, pharmacy intern, or pharmacy technician;
- 69 (7) violating Federal Title II, P.L. 91, Controlled Substances Act, Title 58, Chapter 37,  
70 Utah Controlled Substances Act, or rules or regulations adopted under either act;
- 71 (8) requiring or permitting pharmacy interns or technicians to engage in activities  
72 outside the scope of practice for their respective license classifications, as defined in this  
73 chapter and division rules made in collaboration with the board, or beyond their scope of  
74 training and ability;
- 75 (9) administering:
- 76 (a) without appropriate training, as defined by rule;
- 77 (b) without a physician's order, when one is required by law; and
- 78 (c) in conflict with a practitioner's written guidelines or written protocol for  
79 administering;
- 80 (10) disclosing confidential patient information in violation of the provisions of the  
81 Health Insurance Portability and Accountability Act of 1996 or other applicable law;
- 82 (11) engaging in the practice of pharmacy without a licensed pharmacist designated as  
83 the pharmacist-in-charge;
- 84 (12) failing to report to the division any adverse action taken by another licensing  
85 jurisdiction, government agency, law enforcement agency, or court for conduct that in  
86 substance would be considered unprofessional conduct under this section; and
- 87 (13) as a pharmacist or pharmacy intern, compounding a prescription drug in a dosage  
88 form which is regularly and commonly available from a manufacturer in quantities and  
89 strengths prescribed by a practitioner.

90 Section 2. Section **58-17b-503** is amended to read:

91 **58-17b-503. Exception to unprofessional conduct.**

92 (1) For purposes of this section:

93 (a) "Licensed intermediate care facility for people with an intellectual disability" means  
94 an intermediate care facility for people with an intellectual disability that is licensed as a  
95 nursing care facility or a small health care facility under Title 26, Chapter 21, Health Care  
96 Facility Licensing and Inspection Act.

97 (b) "Nursing care facility" [~~has the same definition as~~] means the same as that term is  
98 defined in Section 26-21-2.

99 (c) "Unit pack" means a tamper-resistant nonreusable single-dose single-drug package  
100 with identification that indicates the lot number and expiration date for the drug.

101 (2) [~~Notwithstanding the provisions of Subsection 58-17b-502(5), a~~] A pharmacist  
102 may:

103 (a) accept and redistribute an unused drug under Part 9, Charitable Prescription Drug  
104 Recycling Act; or

105 (b) accept back and redistribute any unused drug, or a part of it, after it has left the  
106 premises of the pharmacy if:

107 ~~[(a)]~~ (i) the drug was prescribed to a patient in a nursing care facility, [~~a~~] licensed  
108 intermediate care facility for people with an intellectual disability, or state prison facility,  
109 county jail, or state hospital;

110 ~~[(b)]~~ (ii) the drug was stored under the supervision of a licensed health care provider  
111 according to manufacturer recommendations;

112 ~~[(c)]~~ (iii) the drug is in a unit pack or in the manufacturer's sealed container;

113 ~~[(d)]~~ (iv) the drug was returned to the original dispensing pharmacy;

114 ~~[(e)]~~ (v) the drug was initially dispensed by a licensed pharmacist or licensed pharmacy  
115 intern; and

116 ~~[(f)]~~ (vi) accepting back and [~~redistribution~~] redistributing of the drug complies with  
117 federal Food and Drug Administration and Drug Enforcement Administration regulations.

118 Section 3. Section **58-17b-901** is enacted to read:

119 **Part 9. Charitable Prescription Drug Recycling Act**

120 **58-17b-901. Title.**

121 This part is known as the "Charitable Prescription Drug Recycling Act."

122 Section 4. Section **58-17b-902** is enacted to read:

123 **58-17b-902. Definitions.**

124 As used in this part:

125 (1) "Assisted living facility" means the same as that term is defined in Section [26-21-2](#).

126 (2) "Cancer drug" means a drug that controls or kills neoplastic cells and includes a  
127 drug used in chemotherapy to destroy cancer cells.

128 (3) "Charitable clinic" means a charitable nonprofit corporation that:

129 (a) holds a valid exemption from federal income taxation issued under Section 501(a),  
130 Internal Revenue Code;

131 (b) is exempt from federal income taxation under Section 501(c)(3), Internal Revenue  
132 Code;

133 (c) provides, on an outpatient basis, for a period of less than 24 consecutive hours, to  
134 an individual not residing or confined at a facility owned or operated by the charitable  
135 nonprofit corporation:

136 (i) advice;

137 (ii) counseling;

138 (iii) diagnosis;

139 (iv) treatment;

140 (v) surgery; or

141 (vi) care or services relating to the preservation or maintenance of health; and

142 (d) has a licensed outpatient pharmacy.

143 (4) "Charitable pharmacy" means an eligible pharmacy that is operated by a charitable  
144 clinic.

145 (5) "County health department" means the same as that term is defined in Section  
146 [26A-1-102](#).

147 (6) "Donated prescription drug" means a prescription drug that an eligible donor  
148 donates to an eligible pharmacy under the program.

149 (7) "Eligible donor" means a donor that donates a prescription drug from within the  
150 state and is:

151 (a) a nursing care facility;

- 152 (b) an assisted living facility;
- 153 (c) a licensed intermediate care facility for people with an intellectual disability;
- 154 (d) a manufacturer;
- 155 (e) a pharmaceutical wholesale distributor;
- 156 (f) an eligible pharmacy; or
- 157 (g) a physician's office.
- 158 (8) "Eligible pharmacy" means a pharmacy that:
- 159 (a) is registered by the division as eligible to participate in the program; and
- 160 (b) is operated by:
- 161 (i) a county;
- 162 (ii) a county health department;
- 163 (iii) a pharmacy under contract with a county health department;
- 164 (iv) the Department of Health, created in Section [26-1-4](#);
- 165 (v) the Division of Substance Abuse and Mental Health, created in Section
- 166 [62A-15-103](#); or
- 167 (vi) a charitable clinic.
- 168 (9) "Eligible prescription drug" means a prescription drug, described in Section
- 169 [58-17b-904](#), that is not a controlled substance.
- 170 (10) "Licensed intermediate care facility for people with an intellectual disability"
- 171 means the same as that term is defined in Section [58-17b-503](#).
- 172 (11) "Medically indigent individual" means an individual who:
- 173 (a) is eligible to receive Medicaid or Medicare; or
- 174 (b) does not have health insurance and lacks reasonable means to purchase prescribed
- 175 medications.
- 176 (12) "Nursing care facility" means the same as that term is defined in Section
- 177 [26-18-501](#).
- 178 (13) "Physician's office" means a fixed medical facility that:
- 179 (a) is staffed by a physician, physician's assistant, nurse practitioner, or registered
- 180 nurse, licensed under Title 58, Occupations and Professions; and
- 181 (b) treats an individual who presents at, or is transported to, the facility.
- 182 (14) "Program" means the Charitable Prescription Drug Recycling Program created in

183 Section 58-17b-903.

184 (15) "Unit pack" means the same as that term is defined in Section 58-17b-503.

185 (16) "Unlawful conduct" means the same as that term is defined in Sections 58-1-501  
186 and 58-17b-501.

187 (17) "Unprofessional conduct" means the same as that term is defined in Sections  
188 58-1-501 and 58-17b-502.

189 Section 5. Section **58-17b-903** is enacted to read:

190 **58-17b-903. Charitable Prescription Drug Recycling Program -- Creation --**

191 **Requirements.**

192 (1) There is created the Charitable Prescription Drug Recycling Program.

193 (2) The division, in consultation with the board, shall:

194 (a) implement the program, on a statewide basis, to permit an eligible donor to transfer  
195 an eligible prescription drug to an eligible pharmacy for dispensing to a medically indigent  
196 individual;

197 (b) in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act,  
198 make rules necessary to implement the program; and

199 (c) provide technical assistance to entities that desire to participate in the program.

200 Section 6. Section **58-17b-904** is enacted to read:

201 **58-17b-904. Criteria for eligible prescription drugs.**

202 An eligible pharmacy may not accept or dispense an unused prescription drug under the  
203 program unless the unused prescription drug:

204 (1) (a) is in the original sealed unit pack; or

205 (b) is an injectable medication;

206 (2) (a) is unopened; or

207 (b) is a cancer drug packaged in an unopened single-unit dose that has been removed  
208 from a multi-dose package;

209 (3) is accepted and dispensed by the eligible pharmacy before:

210 (a) a beyond use date that appears on the label;

211 (b) the expiration date recommended by the manufacturer; or

212 (c) a date, established by division rule for a specific prescription drug, in accordance  
213 with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, that is later than the date in

214 Subsection (3)(a) or (3)(b);

215 (4) (a) is not adulterated or mislabeled; and

216 (b) the pharmacist or licensed pharmacist technician accepting or dispensing the  
217 prescription drug does not have reason to believe that the prescription drug is adulterated or  
218 mislabeled.

219 Section 7. Section **58-17b-905** is enacted to read:

220 **58-17b-905. Participation in program -- Requirements -- Fees.**

221 (1) An eligible donor or an eligible pharmacy may participate in the program.

222 (2) An eligible pharmacy:

223 (a) shall comply with all applicable federal and state laws related to the storage and  
224 distribution of a prescription drug;

225 (b) shall comply with all applicable federal and state laws related to the acceptance and  
226 transfer of a prescription drug, including 21 U.S.C. Chapter 9, Subchapter V, Part H,  
227 Pharmaceutical Distribution Supply Chain;

228 (c) shall, before accepting or dispensing a prescription drug under the program, inspect  
229 each prescription drug to determine whether the prescription drug is an eligible prescription  
230 drug;

231 (d) may dispense an eligible prescription drug to a medically indigent individual who:

232 (i) is a resident of the state; and

233 (ii) has a prescription issued by a practitioner;

234 (e) may charge a handling fee, adopted by the division under Section [63J-1-504](#); and

235 (f) may not accept, transfer, or dispense a prescription drug in violation of the federal  
236 Food, Drug, and Cosmetic Act, 21 U.S.C. Sec. 301 et seq.

237 Section 8. Section **58-17b-906** is enacted to read:

238 **58-17b-906. Liability of participating organizations and manufacturers.**

239 A person is not liable for injury, death, or loss of property based solely on the fact that  
240 the person donated, accepted, or dispensed an eligible prescription drug under this part.

241 Section 9. Section **58-17b-907** is enacted to read:

242 **58-17b-907. Rules made by the division.**

243 The rules made by the division under Subsection [58-17b-903](#)(2)(b) shall include:

244 (1) registration requirements to establish the eligibility of a pharmacy to participate in



245 the program;  
246 (2) a formulary that includes all eligible prescription drugs approved by the federal  
247 Food and Drug Administration;  
248 (3) standards and procedures for:  
249 (a) verifying whether a pharmacy or pharmacist participating in the program is licensed  
250 and in good standing with the board;  
251 (b) handling of a donated eligible prescription drug, including:  
252 (i) acceptance;  
253 (ii) identification, including redundant criteria for verification;  
254 (iii) documentation, under 21 U.S.C. Sec. 360eee-1, of transaction information, history,  
255 and statements;  
256 (iv) safe storage;  
257 (v) security;  
258 (vi) inspection;  
259 (vii) transfer; and  
260 (viii) dispensing;  
261 (c) a pharmacist or licensed pharmacy technician working in or consulting with a  
262 participating eligible donor;  
263 (d) disposition of a donated prescription drug that is a controlled substance;  
264 (e) record keeping regarding:  
265 (i) the eligible donor that donated each prescription drug;  
266 (ii) the identification and evaluation of a donated prescription drug by a pharmacist or  
267 licensed pharmacy technician; and  
268 (iii) the dispensing or disposition of a prescription drug;  
269 (f) determining the status of a medically indigent individual;  
270 (g) labeling requirements to:  
271 (i) ensure compliance with patient privacy laws relating to:  
272 (A) an individual who receives an eligible prescription drug; and  
273 (B) patient information that may appear on a donated prescription drug;  
274 (ii) clearly identify an eligible prescription drug dispensed under the program; and  
275 (iii) communicate necessary information regarding the manufacturer's recommended

276 expiration date or the beyond use date; and

277 (h) ensuring compliance with the requirements of this part;

278 (4) a process for seeking input from:

279 (a) the Department of Health, created in Section [26-1-4](#), to establish program standards

280 and procedures for assisted living facilities and nursing care facilities; and

281 (b) the Division of Substance Abuse and Mental Health, created in Section

282 [62A-15-103](#), to establish program standards and procedures for mental health and substance

283 abuse clients; and

284 (5) the creation of a special training program that a pharmacist and a licensed pharmacy

285 technician at an eligible pharmacy must complete before participating in the program.

---

---

**Legislative Review Note**  
**Office of Legislative Research and General Counsel**